Burden of Pneumococcal Disease in Hospitalized Children
Author Information
Author(s): Salini Mohanty, Nicole Cossrow, Meghan White, Kalvin C. Yu, Gang Ye, Kristen A. Feemster, Vikas Gupta
Primary Institution: Merck & Co., Inc.
Hypothesis
This study explored the clinical and economic burden of invasive pneumococcal disease, non-invasive all-cause pneumonia, and acute otitis media in hospitalized children.
Conclusion
The burden of pneumococcal disease among hospitalized pediatric patients in the US remains substantial, particularly for young children and those with underlying medical conditions.
Supporting Evidence
- The in-hospital mortality rate was 0.6%, with 28 pediatric patients recorded.
- The median length of stay was 4 days, with a median hospital cost of $4,240 per admission.
- Patients with moderate- or high-risk conditions had significantly poorer outcomes.
- Children under 2 years of age represented 50.7% of the sample size.
Takeaway
Pneumococcal disease is a big problem for kids in the hospital, especially for those under 2 years old or with other health issues.
Methodology
The study analyzed data from the BD Insights Research Database of hospitalized children under 18 years old in the US, focusing on those with specific ICD10 codes for pneumococcal disease.
Potential Biases
Selection bias may have affected antimicrobial resistance rates, as more severely ill patients are more likely to have cultures performed.
Limitations
The study had low representation from certain geographic regions and a small number of patients with culture results.
Participant Demographics
Approximately 50.7% of participants were under 2 years of age, and 45.2% were female.
Statistical Information
P-Value
0.0256
Confidence Interval
95% CI
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website